Agency policy page
Current FDA positionFDA lists promotion patterns it considers false or misleading for compounded drugs.
Use: build the claims taxonomy and source monitor.
Updated August 20, 2026 · U.S. market
FDA compounded-drug promotion signals now require a recurring claims watch.
The decision advantage is not another warning-letter summary. It is a maintained map from the current FDA record to the exact public claims, partner pages, owners, and counsel questions that may need review.
SignalActive enforcement
Source confidenceHigh
Legal effectCase-specific
Next reviewOn source change
Direct answer
What changed—and why it matters.
FDA announced 30 warning letters to telehealth companies in March 2026 over advertising of compounded GLP-1 drugs. Its current telehealth promotion page identifies recurring risk patterns: branding that obscures the actual compounder, “generic” or “same as” comparisons, implications of FDA approval, unsupported safety or effectiveness claims, and references to an “FDA-licensed” pharmacy.
The operational issue is broader than correcting one page after a letter arrives. Claims can reappear across product pages, label images, partner funnels, email, paid ads, and affiliates while FDA records, shortage conditions, bulk-drug policies, and pharmacy relationships change on different timelines.
Editorial judgment
A warning letter is a documented agency position about the cited facts, not a final court judgment and not proof that every current page remains unchanged. The high-confidence conclusion is that recurring source-to-claim monitoring is now a real operating need. Whether a specific statement is lawful requires case-specific counsel review.
Sample decision map
One signal, four records an operator must keep separate.
The brief classifies the source before proposing a review question. That prevents a press release, warning letter, policy page, and current company page from being treated as interchangeable.
Warning letter
Case-specific findingsEach letter applies FDA’s position to identified webpages, images, labels, and statements.
Use: identify concrete claim surfaces; do not generalize beyond the facts.
Current public pages
Live commercial recordCompany and partner pages may be corrected, replaced, or routed across domains after a letter.
Use: compare dated captures; never imply old copy is still live without checking.
Effective legal status
Counsel determination503A and 503B requirements differ, and a warning letter is not final adjudication.
Use: route the precise question and sources to qualified counsel.
What did not change
The signal does not answer every product question.
Compounded drugs are not FDA approved, and FDA does not verify their safety, effectiveness, or quality before marketing. That general fact did not begin with the 2026 letters.
The letters do not decide whether a drug is appropriate for an individual patient, whether every compounded preparation is unlawful, or whether a recipient’s present-day pages still contain the cited language. They also do not replace state-law, pharmacy, advertising, privacy, or professional-practice review.
A credible competing interpretation is that an established compliance team already monitors these records reliably. In that case, a separate intelligence service has no value unless it reduces missed changes, review time, or cross-functional handoff friction enough to justify its cost.
Operator review queue
Five questions to route—not five legal conclusions.
These questions are a triage tool for marketing, operations, pharmacy, compliance, and counsel. They are not legal advice.
- 01
Does the page make clear which licensed pharmacy compounds and dispenses the drug, rather than implying the telehealth company does?
- 02
Could a reader mistake the compounded drug for an FDA-approved product, an FDA-approved generic, or the same as an approved drug?
- 03
Does any page, label image, ad, email, affiliate, or partner page use inconsistent pharmacy, approval, safety, or effectiveness language?
- 04
Can each clinical or comparative claim be traced to evidence that actually supports the visible wording and population?
- 05
Who owns the correction, counsel review, partner escalation, and re-check date if the answer changes?
Primary sources
Audit the brief.
Sources were checked August 20, 2026. Peptide Evidence Watch links to the original record, dates the review, and corrects the brief when the underlying record changes.
Founding intelligence pilot
Five U.S. operator teams
Test this on the records your team actually monitors.
The $250, 30-day pilot includes four briefs, one tailored watchlist, and a feedback loop. The goal is to prove—or disprove—that the service makes a recurring decision faster and more defensible.
4 weekly briefs1 custom watchlist30 days